- Home
- KUKE vs INKT Comparison
KUKE vs INKT Comparison
Compare KUKE & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KUKE
- INKT
- Stock Information
- Founded
- KUKE 2002
- INKT 2017
- Country
- KUKE China
- INKT United States
- Employees
- KUKE N/A
- INKT N/A
- Industry
- KUKE Other Consumer Services
- INKT Medicinal Chemicals and Botanical Products
- Sector
- KUKE Real Estate
- INKT Health Care
- Exchange
- KUKE Nasdaq
- INKT Nasdaq
- Market Cap
- KUKE 86.8M
- INKT 75.7M
- IPO Year
- KUKE 2021
- INKT 2021
- Fundamental
- Price
- KUKE $2.62
- INKT $18.56
- Analyst Decision
- KUKE
- INKT Hold
- Analyst Count
- KUKE 0
- INKT 3
- Target Price
- KUKE N/A
- INKT $37.50
- AVG Volume (30 Days)
- KUKE 9.5K
- INKT 2.9M
- Earning Date
- KUKE 08-05-2025
- INKT 08-12-2025
- Dividend Yield
- KUKE N/A
- INKT N/A
- EPS Growth
- KUKE N/A
- INKT N/A
- EPS
- KUKE N/A
- INKT N/A
- Revenue
- KUKE $9,442,397.00
- INKT N/A
- Revenue This Year
- KUKE N/A
- INKT N/A
- Revenue Next Year
- KUKE N/A
- INKT N/A
- P/E Ratio
- KUKE N/A
- INKT N/A
- Revenue Growth
- KUKE N/A
- INKT N/A
- 52 Week Low
- KUKE $1.45
- INKT $4.56
- 52 Week High
- KUKE $17.50
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- KUKE 29.13
- INKT 51.35
- Support Level
- KUKE $2.58
- INKT $18.54
- Resistance Level
- KUKE $2.96
- INKT $21.50
- Average True Range (ATR)
- KUKE 0.14
- INKT 8.00
- MACD
- KUKE -0.03
- INKT -0.82
- Stochastic Oscillator
- KUKE 20.63
- INKT 16.51
About KUKE Kuke Music Holding Limited
Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.